Selecting the right PEG lipid for LNP formulation is one of the most consequential decisions in nanoparticle design. The PEG-lipid controls particle size, polydispersity, circulation time, and the rate of cellular uptake — yet it typically comprises less than 5 mol% of the total lipid composition. Small changes in PEG chain length, lipid anchor, or molar ratio can shift particle diameter by 30–50 nm and dramatically alter biodistribution.
This article ranks the five most widely used PEG-lipids for lipid nanoparticle formulation, provides head-to-head specifications, and offers practical criteria for selecting the right one for your application. For a broader overview of LNP design principles, see our complete LNP formulation guide.
Quick Comparison Table
| PEG-Lipid | PEG MW (Da) | Lipid Anchor | Total MW (Da) | Shedding Rate | Primary Application |
|---|---|---|---|---|---|
| DMG-PEG12 | ~530 | C14 (DMG) | ~800 | Very fast (minutes–hours) | Rapid-uptake formulations, short-acting |
| DMG-PEG24 | ~1,060 | C14 (DMG) | ~1,330 | Fast (hours) | Standard mRNA/siRNA liver delivery |
| DMG-PEG36 | ~1,590 | C14 (DMG) | ~1,860 | Moderate (hours) | Balanced size control + uptake |
| DMG-PEG45 | ~2,000 | C14 (DMG) | ~2,270 | Moderate (hours–day) | Size-critical formulations, vaccine LNPs |
| mPEG44-DSPE | ~1,940 | C18 (DSPE) | ~2,690 | Slow (days) | Long-circulating, tumor targeting |
1. DMG-PEG12: The Short-Chain, Fast-Shedding Option
DMG-PEG12 features a 12-unit ethylene glycol chain (~530 Da PEG) conjugated to a dimyristoyl glycerol (C14) lipid anchor. It is the shortest PEG-lipid in common use for LNP formulation.
Key specifications: – PEG molecular weight: ~530 Da – Total molecular weight: ~800 Da – Lipid anchor: C14 dimyristoyl glycerol – PEG conformation at typical densities: Mushroom regime
Why it matters:
The short PEG chain provides minimal steric shielding, resulting in the fastest shedding kinetics of any standard DMG-PEG variant. This makes DMG-PEG12 suitable for formulations where rapid cellular uptake is prioritized over extended circulation — local injection applications, for instance, or formulations where a targeting ligand handles cell selectivity.
However, the limited steric coverage means particle size is more difficult to control. At equivalent molar percentages, DMG-PEG12 formulations produce larger particles than longer-chain variants. You may need to increase the molar ratio to 3–5% to achieve particles below 100 nm.
When to use it: – Local delivery (intramuscular, intratumoral) where circulation time is irrelevant – Formulations requiring the fastest possible PEG desorption – Early-stage screening where cost is a consideration
→ View DMG-PEG12 product details
2. DMG-PEG24: The Versatile Standard
DMG-PEG24 carries a 24-unit PEG chain (~1,060 Da) on a C14 DMG anchor. This places it in the molecular weight range most commonly used in preclinical LNP development, offering a practical balance between steric stabilization and shedding kinetics.
Key specifications: – PEG molecular weight: ~1,060 Da – Total molecular weight: ~1,330 Da – Lipid anchor: C14 dimyristoyl glycerol – PEG conformation: Transition between mushroom and brush at 1.5–2 mol%
Why it matters:
DMG-PEG24 occupies a productive middle ground. Its PEG chain is long enough to provide effective size control during nanoprecipitation — formulations at 1.5 mol% typically produce particles in the 70–90 nm range with PDI < 0.15 — while the C14 anchor still permits shedding within hours of intravenous injection.
When to use it: – General-purpose liver-targeted mRNA or siRNA delivery – Formulation screening and optimization campaigns – Applications where you want moderate stealth without compromising uptake
→ View DMG-PEG24 product details
3. DMG-PEG36: Balanced Performance for Process Development
DMG-PEG36 features a 36-unit PEG chain (~1,590 Da) on the same C14 DMG anchor. It sits between PEG24 and PEG45, offering a useful intermediate for formulation optimization studies.
Key specifications: – PEG molecular weight: ~1,590 Da – Total molecular weight: ~1,860 Da – Lipid anchor: C14 dimyristoyl glycerol – PEG conformation: Brush regime at ≥1.5 mol%
Why it matters:
At 36 ethylene glycol units, the PEG chain enters the brush conformation at lower molar fractions than PEG24, providing more efficient steric coverage per molecule. This is particularly relevant during scale-up, where maintaining tight particle size specifications across different mixing platforms (microfluidic vs. impingement jet) becomes critical.
DMG-PEG36 is an excellent choice for systematic chain-length optimization studies. By testing DMG-PEG24, PEG36, and PEG45 at identical molar ratios, you can map the relationship between PEG molecular weight and particle properties in your specific formulation — without the confounding variable of polydispersity that complicates studies with conventional PEG reagents.
When to use it: – Process development and scale-up optimization – Formulations requiring intermediate circulation time – Chain-length screening studies alongside PEG24 and PEG45
→ View DMG-PEG36 product details
4. DMG-PEG45: The Gold Standard for Vaccine and Defined-MW Applications
DMG-PEG45 is the closest monodisperse equivalent to the polydisperse DMG-PEG2000 used in approved mRNA vaccine formulations. Its 45-unit PEG chain (~2,000 Da) provides robust steric stabilization and consistent particle formation.
Key specifications: – PEG molecular weight: ~2,000 Da – Total molecular weight: ~2,270 Da – CAS: 1397695-86-1 – Lipid anchor: C14 dimyristoyl glycerol – PEG conformation: Dense brush at ≥1 mol%
Why it matters:
DMG-PEG45 is the monodisperse replacement for polydisperse DMG-PEG2000 — the PEG-lipid used in the Moderna (mRNA-1273) formulation. With a defined 45-unit PEG chain, it eliminates the molecular weight distribution inherent in polymer-derived PEG2000 (which typically spans 1,500–2,500 Da with a PDI of 1.02–1.05).
The practical consequence: when you use DMG-PEG45, the PEG chain length on every molecule of your LNP surface is identical. This translates to uniform surface coverage, predictable shedding kinetics, and reproducible particle sizes that don’t drift between reagent lots. For GMP manufacturing and regulatory submissions, this level of molecular definition is increasingly expected.
When to use it: – mRNA vaccine formulations (direct replacement for polydisperse DMG-PEG2000) – GMP and clinical-stage development – Applications where regulatory clarity on raw material identity is important – Any application where the ~2,000 Da PEG range is specified
→ View DMG-PEG45 product details
5. mPEG44-DSPE: The Long-Circulating Alternative
mPEG44-DSPE pairs a 44-unit PEG chain (~1,940 Da) with a distearoylphosphatidylethanolamine (C18) lipid anchor. The longer, saturated acyl chains fundamentally change how this PEG-lipid behaves in an LNP context.
Key specifications: – PEG molecular weight: ~1,940 Da – Total molecular weight: ~2,690 Da – Lipid anchor: C18 DSPE (distearoyl phosphatidylethanolamine) – PEG conformation: Dense brush at ≥1 mol% – Shedding kinetics: Days (significantly slower than DMG variants)
Why it matters:
The C18 DSPE anchor integrates more firmly into the lipid nanoparticle membrane than C14 DMG, making mPEG44-DSPE far more resistant to desorption. The PEG layer persists for days rather than hours, which extends circulation half-life substantially.
This persistent stealth is desirable for systemic delivery scenarios — accumulation in solid tumors via the EPR effect, delivery to lymph nodes, or distribution to non-liver tissues. However, the reduced shedding also limits endosomal escape efficiency, because the PEG layer must be removed before the ionizable lipid can interact with the endosomal membrane. Many groups address this by incorporating cleavable PEG-lipid designs or by accepting a degree of reduced per-cell transfection in exchange for broader tissue distribution.
DSPE-based PEG-lipids also have a long history in liposomal formulations (Doxil, for example, uses DSPE-PEG2000) and are well-characterized from a regulatory perspective.
When to use it: – Long-circulating formulations for systemic delivery – Tumor targeting via the EPR effect – Formulations where extended PEG coverage is needed (e.g., repeated dosing where anti-PEG antibodies are a concern) – Liposomal or hybrid nanoparticle formulations
→ View mPEG44-DSPE product details
Selection Criteria: How to Choose
Choosing among these five PEG-lipids comes down to four questions:
1. What Is Your Target Tissue?
Liver (hepatocytes): DMG-PEG24, PEG36, or PEG45. The C14 anchor permits shedding in the hepatic sinusoid, exposing ApoE-adsorbed LNPs to LDLR-mediated uptake. PEG45 is the closest to approved formulations.
Systemic / tumor / extrahepatic: mPEG44-DSPE. The persistent PEG layer enables extended circulation for passive or active targeting.
Local injection (IM, intratumoral): DMG-PEG12 or PEG24. Rapid shedding is acceptable or even desirable for local depot effects.
2. What Particle Size Do You Need?
Longer PEG chains give finer size control at equivalent molar ratios. If you’re targeting <70 nm, DMG-PEG45 at 2–3 mol% is the most straightforward route. For particles of 80–120 nm, DMG-PEG24 at 1–1.5 mol% often suffices.
3. What Stage Is Your Program?
For early discovery, DMG-PEG24 offers the best cost-to-performance ratio. For IND-enabling studies and GMP manufacturing, the molecular definition of DMG-PEG45 (monodisperse, CAS-registered) provides the clearest regulatory path.
4. Do You Need Functional PEG-Lipid?
If you plan to conjugate targeting ligands, antibody fragments, or other moieties to the PEG terminus, consider functionalized variants. PurePeg offers NHS ester, amine, and other reactive DSPE-PEG variants — see the full PEG-Lipid catalog for options.
For additional guidance on matching PEG-lipids to specific applications, our article on choosing the right PEG-lipid provides a decision framework. For fundamentals on PEG-lipid chemistry and nomenclature, see PEG-lipids explained.
The Monodisperse Advantage
A recurring theme across all five products: monodisperse PEG-lipids eliminate a major source of batch variability in LNP manufacturing. Polydisperse PEG2000 reagents contain molecules ranging from ~1,500 to ~2,500 Da, meaning each LNP batch has a different distribution of PEG chain lengths on its surface. This translates directly to variability in particle size, PDI, and shedding kinetics.
Monodisperse alternatives — where every molecule has the same exact number of ethylene glycol units — remove this variable entirely. The result is tighter specifications, fewer failed batches, and cleaner analytical data. As LNP programs advance from discovery through clinical stages, this level of molecular control becomes not just convenient but necessary.
PurePeg’s complete PEG-Lipid catalog includes 39 monodisperse products spanning DMG, DSPE, and DSG chemistries, all with ≥95% purity and defined molecular weights.
Need help selecting the right PEG-lipid for your LNP program? Contact PurePeg’s technical team at 1-888-331-8188 or explore the full PEG-Lipid catalog to compare specifications and place an order.